MAMOON RASHEED: Open Payments
NPI 1760448468 · ROCKVILLE CENTRE, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$936 in 49 payments from 10 companies in 2025. Trend: 2023 $867 · 2024 $904 · 2025 $936
Food & beverage: $936
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $331 |
| AstraZeneca Pharmaceuticals LP | 3 | $160 |
| Lilly USA, LLC | 3 | $138 |
| GlaxoSmithKline, LLC. | 4 | $76 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| PFIZER INC. | 3 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| Novo Nordisk Inc | 1 | $25 |
| Abbott Laboratories | 1 | $22 |
Products named: VRAYLAR, AIRSUPRA, ZEPBOUND, TRELEGY ELLIPTA, FANAPT, Auvelity, QULIPTA, MOUNJARO.
Industry payments across NY — which companies pay providers there.
